| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5599848 | Atherosclerosis Supplements | 2017 | 9 Pages |
Abstract
Evaluation of a lipoprotein landscape when LDL-C levels remain low strongly supports the role of non-HDL-C, Lp(a) and TGs in identifying patients with increased residual risk of CV and in selecting their treatment strategy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Maurizio Averna, Erik Stroes,